Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Besides the main objective, there are 3 other objectives as follows: * To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation * To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration * To investigate biomarkers related to the safety and efficacy of HM61713